Andersen JT, Sandlie I (2009) The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab Pharmacok 24:318–332. https://doi.org/10.2133/dmpk.24.318

Article  CAS  Google Scholar 

Babaee N, Talebkhan Garoosi Y, Karimipoor M, Davami F, Bayat E, Safarpour H, Mahboudi F, Barkhordari F (2020) DARPin Ec1-LMWP protein scaffold in targeted delivery of siRNA molecules through EpCAM cancer stem cell marker. Mol Biol Rep 47:7323–7331. https://doi.org/10.1007/s11033-020-05752-5

Article  CAS  PubMed  Google Scholar 

Berger S, Lowe P, Tesar M (2015) Fusion protein technologies for biopharmaceuticals: applications and challenges. mAbs 7:456–460. https://doi.org/10.1080/19420862.2015.1019788

Article  CAS  PubMed Central  Google Scholar 

Binz HK, Bakker TR, Phillips DJ, Cornelius A, Zitt C, Gottler T, Sigrist G, Fiedler U, Ekawardhani S, Dolado I, Saliba JA, Tresch G, Proba K, Stumpp MT (2017) Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin drug candidate. mAbs 9:1262–1269. https://doi.org/10.1080/19420862.2017.1305529

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS (2006) AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. New Engl J Med 355:1672–1681. https://doi.org/10.1056/NEJMoa054626

Article  CAS  PubMed  Google Scholar 

Caputi AP, Navarra P (2020) Beyond antibodies: ankyrins and DARPins. From basic research to drug approval. Curr Opin Pharmacol 51:93–101. https://doi.org/10.1016/j.coph.2020.05.004

Article  CAS  PubMed  Google Scholar 

Chen X, Zaro JL, Shen W-C (2013) Fusion protein linkers: property, design and functionality. Adv Drug Del Rev 65:1357–1369. https://doi.org/10.1016/j.addr.2012.09.039

Article  CAS  Google Scholar 

Cines DB, Yasothan U, Kirkpatrick P (2008) Romiplostim. Nat Rev Drug Discov 7:887–888. https://doi.org/10.1038/nrd2741

Article  CAS  PubMed  Google Scholar 

Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, Davis AM, Tansik RL, Mattheakis LC, Boytos CM, Schatz PJ, Baccanari DP, Wrighton NC, Barrett RW, Dower WJ (1997) Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276:1696–1699. https://doi.org/10.1126/science.276.5319.1696

Article  CAS  PubMed  Google Scholar 

de Serres M, Yeager RL, Dillberger JE, Lalonde G, Gardner GH, Rubens CA, Simkins AH, Sailstad JM, McNulty MJ, Woolley JL (1999) Pharmacokinetics and hematological effects of the PEGylated thrombopoietin peptide mimetic GW395058 in rats and monkeys after intravenous or subcutaneous administration. Stem Cells 17:316–326. https://doi.org/10.1002/stem.170316

Article  PubMed  Google Scholar 

Feese MD, Tamada T, Kato Y, Maeda Y, Hirose M, Matsukura Y, Shigematsu H, Muto T, Matsumoto A, Watarai H, Ogami K, Tahara T, Kato T, Miyazaki H, Kuroki R (2004) Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci U S A 101:1816–1821. https://doi.org/10.1073/pnas.0308530100

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fiedler U, Ekawardhani S, Cornelius A, Gilboy P, Bakker TR, Dolado I, Stumpp MT, Dawson KM (2017) MP0250, a VEGF and HGF neutralizing DARPin molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models. Oncotarget 8:98371–98383. https://doi.org/10.18632/oncotarget.21738

Article  PubMed  PubMed Central  Google Scholar 

Fischer S, Götze TO, Omlin A, Baird RD, Dawson KM, Zitt C, Arany Z, Tresch G, Fiedler U, Jeger S, Fung S, Legenne P, Leupin N, Schneeweiss A, Fremd C (2022) A case of sustained tumor regression with MP0274, a novel DARPin therapeutic targeting human epidermal growth factor receptor 2 signaling, in metastatic human epidermal growth factor receptor 2–positive breast cancer after prior trastuzumab and pertuzumab. JCO Precis Oncol 6:e2200006. https://doi.org/10.1200/PO.22.00006

Article  PubMed  PubMed Central  Google Scholar 

Gilreath J, Lo M, Bubalo J (2021) Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs 81:1285–1305. https://doi.org/10.1007/s40265-021-01553-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Glaesner W, Mark Vick A, Millican R, Ellis B, Tschang SH, Tian Y, Bokvist K, Brenner M, Koester A, Porksen N (2010) Engineering and characterization of the long-acting glucagon‐like peptide‐1 analogue LY2189265, an fc fusion protein. Diabetes Metab Res Rev 26:287–296. https://doi.org/10.1002/dmrr.1080

Article  CAS  PubMed  Google Scholar 

Imbach P, Crowther M (2011) Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med 365:734–741. https://doi.org/10.1053/j.seminhematol.2013.03.005

Article  CAS  PubMed  Google Scholar 

Jacobs SA, Gibbs AC, Conk M, Yi F, Maguire D, Kane C, O’Neil KT (2015) Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics. Protein Eng Des Sel 28:385–393. https://doi.org/10.1093/protein/gzv040

Article  CAS  PubMed  Google Scholar 

Khodabakhsh F, Salimian M, Hedayati MH, Ahangari Cohan R, Norouzian D (2021) Challenges and advancements in the pharmacokinetic enhancement of therapeutic proteins. Prep Biochem Biotechnol 51:519–529. https://doi.org/10.1080/10826068.2020.1839907

Article  CAS  PubMed  Google Scholar 

Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171–183. https://doi.org/10.1016/j.jconrel.2008.05.010

Article  CAS  PubMed  Google Scholar 

Kuter DJ (2009) Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 60:193–206. https://doi.org/10.1146/annurev.med.60.042307.181154

Article  CAS  PubMed  Google Scholar 

Kuter DJ (2013) The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol 98:10–23. https://doi.org/10.1007/s12185-013-1382-0

Article  CAS  PubMed  Google Scholar 

Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241–3248. https://doi.org/10.1182/blood.v98.12.3241

Article  CAS  PubMed  Google Scholar 

Li R, Yang H, Jia D, Nie Q, Cai H, Fan Q, Wan L, Li L, Lu X (2016) Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL. J Control Release 228:96–106. https://doi.org/10.1016/j.jconrel.2016.03.004

Article  CAS  PubMed  Google Scholar 

Liem-Moolenaar M, Cerneus D, Molloy CJ, End D, Brown KH, de Kam ML, Cohen AF, van Hensbergen Y, Burggraaf J (2008) Pharmacodynamics and pharmacokinetics of the novel thrombopoietin mimetic peptide RWJ-800088 in humans. Clin Pharmacol Ther 84:481–487. https://doi.org/10.1038/clpt.2008.96

Article  CAS  PubMed  Google Scholar 

Lok S, Kaushansky K, Holly RD, Kuijper JL, Loftonday CE, Oort PJ, Grant FJ, Heipel MD, Burkhead SK, Kramer JM, Bell LA, Sprecher CA, Blumberg H, Johnson R, Prunkard D, Ching AFT, Mathewes SL, Bailey MC, Forstrom JW, Buddle MM, Osborn SG, Evans SJ, Sheppard PO, Presnell SR, Ohara PJ, Hagen FS, Roth GJ, Foster DC (1994) Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369:565–568. https://doi.org/10.1038/369565a0

Article  CAS  PubMed  Google Scholar 

Mehic D, Machacek J, Schramm T, Buresch L, Kaider A, Eichelberger B, Haslacher H, Fillitz M, Dixer B, Flasch T, Anderle T, Rath A, Assinger A, Ay C, Pabinger I, Gebhart J (2023) Platelet function and soluble P-selectin in patients with primary immune thrombocytopenia. Thromb Res 223:102–110. https://doi.org/10.1016/j.thromres.2023.01.012

Article  CAS  PubMed  Google Scholar 

Merten H, Brandl F, Zimmermann M, Schaefer JV, Irpinio L, Sand KMK, Nilsen J, Andersen JT, Zangemeister-Wittke U, Pluckthun A (2021) Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling. Eur J Pharm Biopharm 167:104–113. https://doi.org/10.1016/j.ejpb.2021.07.011

Article  CAS  PubMed  Google Scholar 

Molineux G (2011) The development of romiplostim for patients with immune thrombocytopenia. Ann N Y Acad Sci 1222:55–63. https://doi.org/10.1111/j.1749-6632.2011.05975.x

Article  CAS  PubMed  Google Scholar 

Neunert C, Noroozi N, Norman G, Buchanan GR, Goy J, Nazi I, Kelton JG, Arnold DM (2015) Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost 13:457–464. https://doi.org/10.1111/jth.12813

Article  CAS  PubMed  PubMed Central  Google Scholar 

Newland A (2011) What’s new in the management of chronic primary immune thrombocytopenia in adults and the use of thrombopoietin receptor agonists. Med Princ Pract 20:301–302. https://doi.org/10.1159/000324876

Article  PubMed  Google Scholar 

Nomura S (2016) Advances in diagnosis and treatments for immune thrombocytopenia. Clin Med Insights Blood Disord 9:15–22. https://doi.org/10.4137/CMBD.S39643

Article  PubMed  PubMed Central  Google Scholar 

Pollaro L, Hei